[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-squamous-cell-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-squamous-cell-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652243","retlirafusp-alfa-combined-with-chemoradiotherapy-in-unresectable-escc-100652243",false,"NCT07769866","Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC","Retlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer","Inclusion Criteria:\n\n1. Voluntarily sign the written informed consent form and agree to participate in this study;\n2. Pathologically confirmed esophageal squamous cell carcinoma;\n3. Staged as T2-4bN0-3M0 or TXNXM1 (with supraclavicular lymph node metastasis), diagnosed as unresectable locally advanced esophageal cancer (according to the American Joint Committee on Cancer (AJCC) 8th edition);\n4. Aged 18-75 years, male or female;\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n6. No prior anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc.;\n7. Adequate major organ function, meeting the following laboratory criteria:\n\n   Complete blood count: Neutrophil count ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Blood biochemistry: Total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL\u002Fmin; Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;\n8. Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose of study drug, and must use effective contraception during the study period and for at least 3 months after the last dose; Male patients with female partners of childbearing potential must be surgically sterile or agree to use effective contraception during the study period and for 3 months after the last dose.\n\nExclusion Criteria:\n\n1. Prior or concurrent treatment with any of the following:\n\n   1. Any prior or ongoing radiotherapy, chemotherapy, or other anti-tumor agents for malignancy;\n   2. Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (at a dose \\> 10 mg\u002Fday of prednisone or equivalent) within 2 weeks prior to the first dose of study drug. Inhaled or topical corticosteroids, and adrenal hormone replacement at doses \\> 10 mg\u002Fday prednisone or equivalent, are permitted in the absence of active autoimmune disease;\n   3. Receipt of live attenuated vaccines within 4 weeks prior to the first dose of study drug;\n   4. Major surgery or severe trauma within 4 weeks prior to the first dose of study drug;\n2. Tumor-related exclusion criteria:\n\n   1. Non-esophageal cancer patients;\n   2. Patients without unresectable locally advanced or metastatic esophageal cancer;\n   3. Diagnosis of another malignancy within 5 years prior to the first dose of study drug, with the exception of cured cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery;\n3. Other criteria:\n\n   1. Poorly controlled cardiac symptoms or diseases, including: a) New York Heart Association (NYHA) class ≥ 2 heart failure; b) Unstable angina; c) Myocardial infarction within 1 year; d) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n   2. Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; asthma requiring bronchodilators for medical intervention is excluded;\n   3. Pregnant or breastfeeding women;\n   4. History of severe allergic reactions to monoclonal antibodies, platinum agents, paclitaxel, or human serum albumin;\n   5. Human immunodeficiency virus (HIV)-positive patients, or patients with active hepatitis (hepatitis B reference: hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) ≥ 2000 IU\u002FmL or ≥ 10⁴ copies\u002FmL; hepatitis C reference: hepatitis C virus (HCV) antibody positive), or active pulmonary tuberculosis;\n   6. Any other condition that, in the investigator's judgment, may necessitate premature termination from the study.","ALL","18 Years","75 Years",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of retlirafusp alfa combined with radical chemoradiotherapy in the treatment of locally advanced unresectable esophageal squamous cell carcinoma. Participants will receive two cycles of retlirafusp alfa and chemotherapy for induction therapy before standard concurrent chemoradiotherapy and retlirafusp alfa for maintenance treatment till one year.",[27],"Esophageal Squamous Cell Cancer",[27,29,30,31,32,33],"PD-L1","TGF-β","Retlirafusp Alfa","SHR-1701","concurrent chemoradiotherapy","NOT_YET_RECRUITING","2026-08-17",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":21},"2026-09-01",{"date":42,"type":21},"2030-06-30",{"name":44,"class":45},"RenJi Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100561960","lymphocyte-sparing-thoracic-radiotherapy-for-esophageal-squamous-cell-carcinoma-100561960","NCT06596954","Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma","Lymphocyte-sparing Thoracic Radiotherapy vs Conventional Radiotherapy for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Therapy: an Open Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained;\n2. Pathologically confirmed esophageal squamous cell carcinoma;\n3. locally advanced ESCC (cT3-4 or N+);\n4. the age of patients should be more than 18 years, and less than 80 years;\n5. aged between 18 and 80 years;\n6. KPS score of patients should be more than 80\n\nExclusion Criteria:\n\n1. diagnosis of metastatic esophageal cancer;\n2. Patient refuses to receive systemic drug treatment;\n3. clinical diagnosis of pleural metastasis or malignant pleural effusion;\n4. Pregnant or breastfeeding women;\n5. Severe non-cancerous medical comorbidities that affect the implementation of radiotherapy.","80 Years",{"count":56,"type":21},212,[24],"Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with poor prognosis in various solid tumors, including esophageal cancer. The lymphocyte depletion caused by radiotherapy has garnered considerable attention from oncologists. However, there is still a lack of prospective clinical research data on lymphocyte protection in thoracic tumors. Therefore, this study aims to provide high-level evidence from evidence-based medicine regarding the correlation between lymphocyte depletion and prognosis in esophageal cancer patients, offering more effective strategies and methods to improve the outcomes of neoadjuvant chemoradiotherapy for esophageal cancer.",[27],[61,62,63,64],"esophageal cancer","neoadjuvant treatment","lymphocyte-sparing radiotherapy","prognosis","RECRUITING","2026-08-10",{"date":68,"type":38},"2026-08-11",{"date":70,"type":38},"2024-06-30",{"date":72,"type":21},"2027-12-30",{"name":74,"class":45},"Ruijin Hospital",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100557993","phase-1-study-of-xb010-in-subjects-with-solid-tumors-100557993","NCT06545331","Study of XB010 in Subjects With Solid Tumors","A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors","* Age 18 years or older on the day of consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Adequate organ and marrow function.\n* Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.\n\n  * The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer).\n* Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.",{"count":83,"type":21},396,[85],"PHASE1","This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.",[88,27,89,90,91,92],"Locally Advanced or Metastatic Solid Tumors","Head and Neck Squamous Cell Cancer","NSCLC (Non-small Cell Lung Cancer)","Hormone-receptor-positive Breast Cancer","Triple Negative Breast Cancer (TNBC)","2026-06-17",{"date":95,"type":38},"2026-06-22",{"date":97,"type":38},"2024-08-06",{"date":99,"type":21},"2027-10-20",{"name":101,"class":102},"Exelixis","INDUSTRY",20]